-
Ad-hoc-Mitteilung gem盲ss Art. 53 KR Pratteln, Schweiz, 31.聽Mai 2023 鈥� Santhera Pharmaceuticals (SIX: SANN) gibt die Ver枚ffentlichung des Jahresberichts 2022 mit den vollst盲ndig gepr眉ften Ergebnissen...
-
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May聽31, 2023 鈥� Santhera Pharmaceuticals (SIX: SANN) announces the publication of its Annual Report 2022 with fully audited results...
-
Ad-hoc-Mitteilung gem盲ss Art. 53 KR Santhera wird am 27. April 2023 um 14:30 MESZ / 13:30 BST / 08:30 EDT eine Telefonkonferenz durchf眉hren. Details dazu am Ende dieser Mitteilung. Ums盲tze...
-
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 27, 2023, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Revenue from...
-
Pratteln, Schweiz, und Rockville, MD, USA, 25. April 2023 -- Santhera Pharmaceuticals (SIX: SANN) und ReveraGen BioPharma, Inc. geben bekannt, dass die U.S.-Gesundheitsbeh枚rde FDA das Mid-Cycle Review...
-
Pratteln, Switzerland, and Rockville, MD, USA, April聽25, 2023 鈥� Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce the successful completion of the mid-cycle review meeting by...
-
Pratteln, Schweiz, 2.聽M盲rz 2023 鈥� Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass das Unternehmen bei der britischen Arzneimittelbeh枚rde MHRA (Medicines and Healthcare products Regulatory...
-
Pratteln, Switzerland, March聽2, 2023 鈥� Santhera Pharmaceuticals (SIX: SANN) announces that it has submitted a marketing authorization application (MAA) to the UK Medicines and Healthcare products...
-
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad-hoc-Mitteilung gem盲ss Art. 53 KR Finanzierung bezweckt die...
-
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Funding intended to...